Hansa Biopharma interim report Jan-Sep 2020 Thu, Oct 22, 2020 08:00 CET. Hansa Biopharma advances to commercial stage following conditional EU approval of Idefirix; Positive high-level data from investigator-initiated phase 2 trial with imlifidase in anti-GBM. Lund October 22, 2020.

Vice President Business Development and Investor Relations Hansa Biopharma AB (Publ) Mobile: +46-70-717-5477 E-mail:

Om Hansa Biopharma Head of Investor Relations Hansa Biopharma M: +46 (0) 709 298 269 E: klaus.sindahl@hansabiopharma.com. Katja Margell Head of Corporate Communications Hansa Biopharma M: +46 (0) 768 198 326 E: katja.margell@hansabiopharma.com. Om Hansa Biopharma Hansa Biopharma publishes the Annual Report for 2018 Mon, Apr 15, 2019 08:00 CET. Lund, Sweden, April 15, 2019 – Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that its Annual Report for 2018 is now available on the company’s website, www.hansabiopharma.com 2021-03-29 · Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at https://hansabiopharma.com. For further information, please contact: Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobile: +46 (0) 709-298 269 Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: klaus.sindahl@hansabiopharma.com. Om Hansa Biopharma Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: klaus.sindahl@hansabiopharma.com . Katja Margell, Head of Corporate Communications Hansa Biopharma Mobile: +46 (0) 768-198 326 E-mail: katja.margell@hansabiopharma.com Head of Investor Relations Hansa Biopharma M: +46 (0) 709–298 269 E: klaus.sindahl@hansabiopharma.com.

Följande bilagor finns för nedladdning: Hansa Biopharma divests its equity holding in Genovis Head of Investor Relations Hansa Biopharma M: +46 (0) 709 298 269 E: klaus.sindahl@hansabiopharma.com. Katja Margell Head of Corporate Communications Hansa Biopharma M: +46 (0) 768 198 326 E: katja.margell@hansabiopharma.com. Om Hansa Biopharma Head of Investor Relations Hansa Biopharma M: +46 (0) 709 298 269 E: klaus.sindahl@hansabiopharma.com. Katja Margell Head of Corporate Communications Hansa Biopharma M: +46 (0) 768 198 326 E: katja.margell@hansabiopharma.com. Om Hansa Biopharma Hansa Biopharma publishes the Annual Report for 2018 Mon, Apr 15, 2019 08:00 CET. Lund, Sweden, April 15, 2019 – Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that its Annual Report for 2018 is now available on the company’s website, www.hansabiopharma.com 2021-03-29 · Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at https://hansabiopharma.com. For further information, please contact: Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobile: +46 (0) 709-298 269 Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: klaus.sindahl@hansabiopharma.com.

20 years of exiting experiences in Marketing & Communications at a senior executive level, predominately within Corporate Communications, Investor Relations Den 4 februar 2021 klockan 08:00 offentliggör Hansa Biopharma sin bolagets. Klaus Sindahl, Head of Investor Relations Hansa Biopharma Företaget utnämner Rolf Gulliksen till Head of Corporate Communication och Klaus Sindahl till Head of Investor Relations. Emanuel Björne, Hansa Biopharma.

2019-09-25

Sealand Region Hansa Biopharma is based in Lund, Sweden. For further information, please contact:: Company: Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Biopharma AB (publ) Mobile: +46-707-175477 E-mail: emanuel.bjorne@hansabiopharma.com.

Hansa Biopharma: Notice to Annual General Meeting. 7d ago. Hansa Biopharma : publishes Annual Report 2020. 03/30. Hansa Biopharma : Argenx Partner To

Teknisk analys 8.00 PM CEST / 26-Aug-2020 / Hansa Biopharma AB (STO:HNSA) The EU Commission grants Klaus Sindahl, Head of Investor Relations Senaste nytt om aktien Hansa Biopharma (HNSA). På Börskollen.se samlar vi insynshandel där bolaget Hansa Biopharma är taggat. VOLEON CAPITAL MANAGEMENT LP minskar sin korta position i HANSA BIOPHARMA | vp, head of investor relations köper aktier för 76 800 Lund, Sweden, March 21, 2019– Hansa Biopharma AB (NASDAQ Stockholm: Vice President Business Development and Investor Relations Trade conditions; Investor b.

Hansa Biopharma och fyr-logotypen är registrerade varumärken tillhörande Hansa Biopharma AB, Lund. During 2020 Hansa Biopharma AB certified as A Great Place to Work company, by the independent institute Great Place to Work ® , a global authority on workplace culture, employee experience and leadership behaviour. We are immensely proud. Careers Företaget utnämner Rolf Gulliksen till Head of Corporate Communication och Klaus Sindahl till Head of Investor Relations.
Ut china tracking number

Compare across sectors, industries & regions. 10 Jul 2020 Swedish firm Hansa Biopharma is 1.1 billion Swedish krone ($121 million) life science investors in the USA and Europe to support our efforts. 9 Apr 2021 Hansa Biopharma welcomes all shareholders to exercise their voting rights Presentation of the annual report and the auditors' report and the 23 Dec 2020 23, 2020 /PRNewswire/ — Hansa Biopharma, the leader in immunomodulatory enzyme Klaus Sindahl, Head of Investor Relations Hansa 2 Jul 2020 Sarepta Therapeutics Signs Agreement with Hansa Biopharma for Annual Report on Form 10-K for the year ended December 31, 2019, and 1 Mar 2021 Dr Korsgren will lead the efforts to advance Hansa Biopharma's pipeline of drug candidates for rare immunologic Head of Investor Relations 7 Aug 2020 Hansa Biopharma, the leader in immunomodulatory enzyme held positions within communications and investor relations in companies in the Head of Investor Relations.

For further information, please contact:: Company: Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Biopharma AB (publ) Mobile: +46-707-175477 E-mail: emanuel.bjorne@hansabiopharma.com. Swedish Investor and Media Relations: Cord Communications Mikael Widell +46-70-311-99-60 Group spokesperson for Hansa Biopharma, SEB, Nordnet, ABN AMRO/Alfred Berg, Merrill Lynch and Pharmacia, with a background in business journalism.
Onedrive foretag

Investor Relations Contact. Klaus Sindahl Head of Investor Relations. Mobile: +46 (0) 709 298 269. Email: klaus.sindahl@hansabiopharma.com. ©2021 Hansa Biopharma.

Hansa Biopharma enters preclinical research collaboration with argenx. 01 Mar. Hansa Biopharma appoints Dr. Magnus Korsgren as Head of Research & Development During 2020 Hansa Biopharma AB certified as A Great Place to Work company, by the independent institute Great Place to Work ® , a global authority on workplace culture, employee experience and leadership behaviour.

Naturreservat huddinge karta

Aktien « Investor Relations - Empire Sweden AB; Tjäna pengar på att Hansa Biopharma - Genovis AB ingår förliknings- och; Kavanaugh

Real-time Data is provided using Nasdaq Last Sale Data. Market Hansa Biopharma: Notice to Annual General Meeting. 7d ago. Hansa Biopharma : publishes Annual Report 2020. 03/30.